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ABSTRACT: 3-Helix micelles have demonstrated excellent in vitro and in
vivo stability. Previous studies showed that the unique design of the peptide−
polymer conjugate based on protein tertiary structure as the headgroup is
the main design factor to achieve high kinetic stability. In this contribution,
using amphiphiles with different alkyl tails, namely, C16 and C18, we
quantified the effect of alkyl length on the stability of 3-helix micelles to
delineate the contribution of the micellar core and shell on the micelle
stability. Both amphiphiles form well-defined micelles, <20 nm in size, and
show good stability, which can be attributed to the headgroup design. C18-
micelles exhibit slightly higher kinetic stability in the presence of serum
proteins at 37 °C, where the rate constant of subunit exchange is 0.20 h−1 for
C18-micelles vs 0.22 h−1 for C16-micelles. The diffusion constant for drug
release from C18-micelles is approximately half of that for C16-micelles. The
differences between the two micelles are significantly more pronounced in terms of in vivo stability and extent of tumor
accumulation. C18-micelles exhibit significantly longer blood circulation time of 29.5 h, whereas C16-micelles have a circulation
time of 16.1 h. The extent of tumor accumulation at 48 h after injection is ∼43% higher for C18-micelles. The present studies
underscore the importance of core composition on the biological behavior of 3-helix micelles. The quantification of the effect of
this key design parameter on the stability of 3-helix micelles provides important guidelines for carrier selection and use in
complex environment.
■ INTRODUCTION
Micellar nanoparticles have been studied extensively for use as
nanocarriers for imaging and drug delivery.1−14 Control over
stability of micelles is critical to optimize their pharmacoki-
netics, biodistribution, and clearance mechanism.15−18 Funda-
mental studies focused on the molecular design parameters that
can be used to tune micelle stability have been instrumental in
generating stable polymeric nanocarriers in the size range of
50−150 nm.19−25 Recent studies have established advantages of
smaller nanocarriers in the size range of 10−30 nm, in terms of
favorable transport properties in blood circulation, facile
extravasation from vasculature to tumor tissues, and homoge-
neous distribution in tumor.14,18,26,27 We recently reported the
design of 15 nm 3-helix micelles based on an amphiphile with
headgroup of PEG attached to the exterior of a coiled-coil 3-
helix bundle.18 Intravenous administration of doxorubicin
(DOX) loaded 3-helix micelles in mice indicated increased
tumor accumulation with extended drug half-life and reduced
side effects.14
The unique design of the 3-helix micelle headgroup,
consisting of a polymer-conjugated coiled-coil helix bundle,
imparts the micelles with excellent kinetic stability.28 The
protein tertiary structure in the headgroup allows entropic
repulsions between the polymer chains that slows the subunit
exchange and stabilizes 3-helix micelles.28 Studies of PEG-lipid
micelles have shown that increasing the length of the alkyl tails
leads to decreased in vitro subunit exchange and higher
stability.29 However, the stability of 3-helix micelles as a
function of tail hydrophobicity has not been quantified. These
quantitative studies should provide critical guidelines to design
and formulate 3-helix micelles with tunable stability for a range
of applications for nanocarriers. In addition to understanding
the effect of the alkyl tail on the in vitro stability of 3-helix
micelles, it is equally, if not more, critical to evaluate the effect
of relevant design parameters on in vivo stability of micelles to
establish if the results from in vitro analytical characterization
can be used as a guideline for in vivo studies and to predict
micelle stability in biological environments.
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Our initial design consists of an amphiphile comprising a
coiled-coil peptide (1coi) conjugated to stearic acid (C18) at
the N-terminus and PEG-2000 Da (P2K) at the middle of the
peptide backbone, which is called “1coi-dC18-P2K”. Con-
jugation of a PEG-750 Da (P750) chain at the C-terminus
results in “1coi-dC18-P2K-P750″, and micelles based on this
amphiphile were used for in vivo evaluation.18 The physical
characterization of kinetic stability of 3-helix micelles was
performed using micelles assembled from “1coi-dC16-P2K”,
without P750 chains required for stealth layer, in our earlier
work.28 Here, we present a systematic investigation of the effect
of the core forming alkyl chains on the size, core packing, drug
release kinetics, in vitro and in vivo stability, and biodistribution
of 3-helix micelles. In this study, amphiphiles have identical
headgroups based on peptide−PEG conjugate 1coi-P2K-P750,
and the hydrophobic alkyl tails are C16 and C18, respectively
(Scheme 1), which allows evaluation of the exclusive effect of
alkyl tails on 3-helix micelle stability. We denote the micelles as
“C16-micelle” and “C18-micelle” The differences between the
two micelles in terms of their in vitro stability and cargo release
kinetics are minimal. However, the difference in blood
circulation time of the two micelles is more pronounced than
that shown by in vitro studies. These results demonstrate the
importance of enthalpic contributions from alkyl chains in the
micellar core, in addition to the entropic repulsion in the
headgroup, toward micelle stability, most notably in biological
conditions in vivo.
The desirable circulation times of nanoparticles vary for
different applications. For example, faster accumulation at the
target site, along with rapid blood clearance, is advantageous for
imaging with high contrast and a high signal-to-noise ratio. On
the other hand, longer circulation times would result in
increased exposure of the nanocarrier to the vasculature, and
hence would be useful for targeting blood vessels and other
components in vasculature. Nanocarriers with longer blood
circulation time are also attractive for the passive targeting of
tumor tissue.30−32 The quantitative evaluations in this study
provide a useful guideline to tailor the in vivo stability and the
blood circulation time of 3-helix micelles for different biological
applications.
■ EXPERIMENTAL SECTION
Synthesis of Peptide−Polymer Conjugate. The design of the
two amphiphilic conjugates is based on a 3-helix bundle peptide
designed de novo, 1coi (EVEALEKKVAALECKVQALEKKVEALE-
HGW).33 Aliphatic tails of palmitic acid (C16) and stearic acid (C18)
were conjugated to the N-terminus of the peptide to investigate the
effect of hydrophobicity of alkyl tails on assembly and stability of C16-
and C18-micelles. The details of the materials and the synthesis of
amphiphilic peptide−polymer conjugate have been described
previously.18 Conjugates were purified by reverse-phase high pressure
liquid chromatography (RP-HPLC). 1coi-dC16-P2K-P750 conjugates
were eluted with a linear AB gradient, where solvent A consisted of
water plus 0.1% (v/v) TFA and solvent B consisted of acetonitrile plus
0.1% (v/v) TFA. For 1coi-dC18-P2K-P750, solvent B was isopropanol
plus 0.1% (v/v) TFA. A linear gradient of 30% to 100% B over 30 min
was used for both conjugates, with typical elution of amphiphiles at
∼85% B.
Biophysical Characterization of C16- and C18-Micelles. C16-
and C18-micelles were prepared by direct dissolution of the
lyophilized powder in phosphate buffer (25 mM, pH 7.4). The
solutions were annealed at 70 °C for an hour to allow equilibration of
micelle assembly. The annealed solutions were cooled down to room
temperature before use. Dynamic light scattering (DLS) size
measurements were made on a Malvern Zetasizer Nano-ZS with a
633 nm laser and a scattering angle of 17°. Size exclusion
chromatography (SEC) was carried out on a BioSep-SEC-S 4000
column (Phenomenex), with a flow rate of 1 mL/min, and 25 mM
phosphate buffer, pH 7.4, was used as the elution solvent. Small angle
X-ray scattering (SAXS) was carried out at beamline 7.3.3 at the
Advanced Light Source, Lawrence Berkeley National Laboratory.
Details on the sample preparation and data analysis for SAXS
measurements can be found in our earlier work.28 Circular dichroism
(CD) measurements were made were made on a Jasco J810
spectropolarimeter from 260 to 190 at 0.2 nm intervals, a rate of a
100 nm/min, a response time of 4 s, and a bandwidth of 1 nm.
Differential scanning calorimetry (DSC) was performed on a VP-
MicroCal (GE), as temperature was increased from 5 to 60 °C at a rate
of 1 °C/min. DSC thermograms were obtained after concentration
normalization and baseline correction with Origin software provided
by MicroCal. The enthalpy change associated with alkyl chain phase
transition was calculated by using the area under the curve function in
Igor Pro 6. A concentration of 2 mg/mL was used for both CD and
DSC measurements. The in vitro stability of micelles in serum albumin
was studied by Förster resonance energy transfer (FRET) from
micelle-encapsulated donor/acceptor dyes, as described previously.18
A lipophilic FRET pair, 3,3′-dioctadecyloxacarbocyanine perchlorate
(DiO, donor) and 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocya-
nine perchlorate (DiI, acceptor), were used to measure the energy
transfer upon mixing. The emission spectra were recorded in the range
of 475 to 650 nm for 12 h with excitation wavelength at 450 nm. The
efficiency of energy transfer between the dyes is characterized by
FRET ratio, defined as I565/(I565 + I505), where I is fluorescence
intensity at the respective wavelength.
Loading and Release of DOX from Micelles. The loading of
DOX in 3-helix micelles was performed by the thin film hydration
method as described in earlier work.14 The release profiles of DOX
from micelles were studied using the dialysis bag technique at 37 °C.
The solution of DOX-loaded micelles (3 mg/mL, 2 mL) was placed in
a dialysis bag (Spectrum Laboratories, MWCO 3500 Da). The dialysis
bag was immersed in 500 mL of PBS solution (25 mM, pH 7.4) in a
glass beaker, which was stirred at 600 rpm. Ten microliters of solution
was drawn from a dialysis bag at desired time intervals and the drug
concentration was analyzed using RP-HPLC. DOX release profiles
were fit to a Higuchi model for diffusive release, described by Q =
2Co(Dt/π)
1/2, where Q is the amount of drug released per unit area, Co
is the initial drug concentration in the micelle, t is the time in seconds,
Scheme 1. Schematics of 3-Helix Micelle Depicting the
Choice of Two Alkyl Tails with Different Chain Length and
Hydrophobicitya
aQuantification of the effects of the alkyl tail on in vitro and in vivo
stability of 3-helix micelles was performed to establish the significance
of core composition for design of nanocarriers with tunable stability.
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and D is the apparent diffusion constant.34 The Higuchi equation can
be rearranged to obtain fractional drug release, f, as f = kt1/2, with the
Higuchi rate constant, k = (36D/πR2)1/2, where R is the radius of the
micelle.
PET Imaging and Biodistribution. All animal studies were
conducted under a protocol approved by the University of California,
Davis, Animal Care and Use Committee. 64CuCl2 was purchased from
Washington University (St Louis, MO). The details of the synthesis of
radiolabeled micelles and PET imaging scans are described in previous
work.18 In brief, the pharmacokinetics and in vivo biodistribution of
C16- and C18-micelles were studied by positron emission tomography
(PET) and an automatic gamma counter (PerkinElmer, CT),
respectively, after intravenous administration of the micellar solution
to female FVB mice (n = 6 for C18-micelles, (371 ± 107 μCi and 0.68
± 0.15 mg per mouse) and n = 4 for C16-micelles, (407 ± 9 μCi and
0.69 ± 0.008 mg/mouse) bearing new deletion mutant (NDL)35,36
tumors implanted bilaterally within the mammary fat pads. All PET
images and the organ distribution of 64Cu-labeled micelles presented
here have been decay corrected.
■ RESULTS AND DISCUSSION
The synthesis and characterization of 1coi-dC18-P2K-P750 has
been described previously.18 Mass spectroscopy of 1coi-dC16-
P2K-P750 (Supporting Information Figure SI1) shows average
molecular weight of 7150 Da, consistent with the theoretical
weight of 7153 Da. Both amphiphiles form micelles with a
uniform size distribution as confirmed by DLS and SEC
(Supporting Information Figure SI2). There are no adverse
effects of conjugation of C16 and C18 chains on the secondary
and tertiary structure of 1coi, with peptide helicity ∼82% in
both amphiphiles, maintained at the level similar to peptide
alone (Supporting Information Figure SI3). The peptide
structure is stabilized after conjugation of hydrophobic alkyl
tails, as observed previously37,38 (Supporting Information
Figure SI4). Figure 1 shows the SAXS profiles of both micelles
in solution. Using a core−shell spherical model, the radius of
the core of C16-micelles is ∼2.8 nm and thickness of shell is
∼5.7 nm, giving an overall diameter of ∼17 nm. For C18-
micelles, the core radius is ∼3.0 nm with shell thickness ∼5.8
nm, which corresponds to diameter of ∼17.6 nm. The alkyl
chain length has minimal, if any, effect on the hydrodynamic
size of micelles and the structure and thermal stability of the
peptide in the headgroup. Any differences in terms of in vitro
stability, pharmacokinetics, and biodistribution observed
between the two micelles can be safely attributed to the effect
of core chain hydrophobicity. Hence, 3-helix micelles provide a
good model system to understand the effect of a relevant design
parameter (alkyl chain length in the present study), exclusively
on the biological stability of smaller particles, <20 nm in size,
intended for nanocarrier applications.
DSC was performed to characterize the packing of alkyl
chains in the micelle core. Both micelles show an endothermic
phase transition, consistent with a change in alkyl chain packing
in the core of micelles (Figure 2). For C16-micelles, the
transition temperature is 15 °C with the enthalpy associated
with the phase transition being ∼0.408 cal/g. For C18-micelles,
the transition temperature is 24 °C, and the enthalpy associated
with the transition is ∼0.674 cal/g. The transition enthalpies for
both chains in the micelle core are significantly smaller
compared to that in bulk and can be attributed to the packing
of alkyl tails in a curved geometry in micelle core. These results
are in agreement with previous studies, where an increase in the
chain length of the hydrophobic tails leads to an increase in the
melting temperature and transition enthalpy of the alkyl chains
in hydrophobic core of micelles.39−41
The effect of the alkyl tail length on the stability of 3-helix
micelles at physiological temperature (37 °C) was studied to
estimate their suitability in vivo. Quantification of the in vitro
half-life of 3-helix micelles was performed by monitoring the
changes in FRET from C16- and C18-micelles coencapsulated
with donor−acceptor pair (DiO−DiI) dyes. As shown in Figure
3A and 3B, the emission spectra show a major peak at 565 nm
and a minor peak at 505 nm. The increase in emission intensity
at 505 nm as a function of time indicates subunit exchange and
Figure 1. SAXS of C16- and C18-micelles dissolved in phosphate
buffer (25 mM, pH 7.4), both at a concentration of 5 mg/mL. Fitting
of the data (solid lines) in a q range of 0.03−0.1 Å−1 to a core−shell
spherical form factor yields core radii of ∼2.8 nm for C16, and ∼3 nm
for C18-micelles. Shell thickness is calculated to be ∼5.7 nm for both
micelles.
Figure 2. DSC thermograms for C16 and C18-micelles dissolved in
phosphate buffer (25 mM, pH 7.4), both at concentration of 2 mg/
mL. The phase transition temperature for C16-micelle core is 15 °C,
and that for C18-micelle core is 24 °C. The higher transition
temperature for C18-micelles is consistent with higher hydrophobicity
of C18 alkyl chains.
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release of FRET dyes from the micelle. Figure 3C shows the
normalized FRET ratio of I565/(I565 + I505) for the two micelles
as a function of time. After 12 h, FRET ratios for C16- and
C18-micelles are 0.892 and 0.945, respectively. The change of
the FRET ratio with time, fitted to an exponential decay, gives
the decay rate constants (η), which are 0.22 h−1 for C16-micelle
and 0.20 h−1 for C18-micelle, respectively. The half-life (t1/2)
corresponding to the first-order decay constant is 3.15 and 3.46
h for C16- and C18-micelles, respectively. As a reference, the
decay rate constant, η, is 1.24 h−1 for DSPE-PEG micelles.
Thus, both C16- and C18-micelles have fairly high stability,
with C18-micelles being slightly better. The overall good
kinetic stability can be attributed to the unique headgroup
design where the 3-helix bundle positions compressed PEG
chains to impart entropic repulsion to achieve superior stability
relative to DSPE-PEG micelles.28 However, it is worthwhile to
note that the higher value of η for C16-micelles as compared
with C18-micelles indicates that the alkyl chains also have
some, although not drastic, effect on the in vitro stability of
micelles although the alkyl chains were in a molten state.
These studies show that the subunit exchange from C18-
micelles is slightly smaller relative to C16-micelles. Previous
studies with DSPE-PEG micelles showed significant micelle
stabilization when the temperature was below the melting
temperature of alkyl chain in the micelle core.39 In our case, the
physiological temperature is well above the transition temper-
atures of both C16- and C18-micelles, and hence the alkyl
chains in the micelle core are in a disordered/molten state.
Greater hydrophobicity of C18 alkyl tails would result in larger
intermolecular interactions between alkyl tails in the core of
C18-micelles that would lead to slower subunit exchange. From
a thermodynamic perspective, the physical state of alkyl chains
in the molten micelle core would also affect micelle stability at a
given temperature. The further the temperature is from the
melting transition, the more “liquid” like the chains would be,
with higher mobility. Hence, the activation barrier for subunit
exchange would be inversely related to the difference in
temperature of the experiment and transition temperature
measured by DSC, as given by (37 °C − Tm). The smaller
temperature difference (37 °C − Tm) for the C18-micelle and
Figure 3. Emission spectra of (A) C16 (B) C18-micelles encapsulated with donor/acceptor pair of FRET dyes. Micelles are dissolved in phosphate
buffer (25 mM, pH 7.4) at a concentration of 0.2 mg/mL. The changes in fluorescence intensity are monitored for 12 h in the presence of serum
albumin (50 mg/mL) at 37 °C. The excitation wavelength was 450 nm and the emission spectra are recorded from 475 to 650 nm. (C) Plot of
normalized FRET ratio as a function of time for different micelles. The solid lines are the exponential fits to the decay observed. The fitting of the
data gives decay constant (η), which is an indicator of micelle stability. The values of η obtained by fitting for different micelles are 0.22 h−1 for C16-
micelles; 0.20 h−1 for C18-micelles; 1.24 h−1 for DSPE-PEG micelles.
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more hydrophobic C18 chains lead to slower subunit kinetics
and result in their higher stability relative to C16-micelles.
The effect of the alkyl tail on cargo loading and cargo release
kinetics from 3-helix micelles was quantified using DOX as a
model drug. The DOX loading was 7.3 ± 0.5 wt % in C16-
micelles, and 7.8 ± 0.4 wt % in C18-micelles. The size,
uniformity of size distribution, and aqueous solubility of both
micelles were maintained after DOX incorporation. Quantifi-
cation of drug release by the dialysis technique shows sustained
release from both micelles (Figure 4A). For C16-micelles, ∼8%
of DOX is released within 1 h, followed by ∼22% after 24 h,
whereas only 1% DOX is released from C18-micelles within the
initial first hour, followed by ∼10% at 24 h. The release of DOX
from both micelles is comparable to optimized block copolymer
formulations that exhibit DOX release in the range of 20−40%
after 24 h.42−44 In the absence of degradation and swelling of
micelles, DOX release could be fit to the Higuchi model based
on diffusive release with reasonable accuracy (Figure 4B). The
Higuchi rate constants obtained from linear fits are 0.034 h−1/2
for DOX release from C16-micelles and 0.024 h−1/2 from C18-
micelles, which correspond to diffusion constants of 1.57 ×
10−20 and 7.85 × 10−21 cm2/s, respectively. Diffusion constants
in the range of 10−15−10−18 cm2/s have been reported for the
release of variety of cargo molecules from block copolymer
micelles.45,46 The core hydrophobicity affects the micelle
stability, micelle−drug interactions, and thus the rate of drug
release. The diffusion constants for DOX release from both
micelles are significantly smaller, which suggests small drug
leakage from 3-helix micelles. Again, this can be attributed to
the overall stability of 3-helix micelle originating from the
unique headgroup design. However, it is worthwhile to note
that the diffusion constant of DOX from C18-micelles is an
order of magnitude lower than that from C16-micelles.
The observed differences between the two micelles in terms
of in vitro stability are small, and it is important to quantify the
extent of difference in their in vivo stability to establish the
design principles of 3-helix micelles for various biological
applications. The in vivo stability of C16-micelles in mice was
assessed by PET in the present study and compared to that of
C18-micelles reported previously.18 64Cu-labeled micelles were
intravenously administered to mice bearing NDL tumors. PET
images in Figure 5 depict the differences in the accumulation
and clearance of radioactivity between C16- and C18-micelles.
Projected whole body images show that the radioactivity from
C16-micelles is cleared from the blood pool and secreted
through the intestinal tract faster than that of C18-micelles
(Figure 5). The absorbed C-16 micelles in liver can dissociate
and are rapidly secreted with biliary phosphatidylcholine as
previously reported.47 The time activity curve of the radio-
labeled micelles in blood shows that the radioactivity of C16-
micelles at 24 (12.03 ± 0.32% ID/cc) and 48 h (5.81 ± 0.23%
ID/cc) is significantly lower than that of C18-micelles at 24
(25.74 ± 1.77% ID/cc, p < 0.0001) and 48 h (15.17 ± 1.58%
Figure 4. (A) Release profile of DOX from C16- and C18-micelles. Drug loaded micelle solutions (3 mg/mL, 2 mL) were placed in dialysis bags
with MWCO 3500 Da, and release was monitored by quantification of drug in micelles at different times as determined by HPLC. (B) Fits of DOX
release to Higuchi model for diffusive release. Solid lines show the fits of the data to Higuchi equation, given by f = kt0.5, where f is fractional drug
release, t is time, and k is Higuchi constant. The values of k obtained by fits are 0.024 h−1/2 for C16-micelles, and 0.034 h−1/2 for C18-micelles.
Figure 5. Evaluation of in vivo micelle stability by positron emission
tomography (PET). The images acquired at 0, 24, and 48 h are
presented. Top row: projection PET images after the intravenous
administration of 64Cu-labeled C16- and C18-micelles through the tail
vein in mice. Lower row: transverse view of PET images. Arrows
shown indicate the tumor (T, orange), heart (H, white), liver (L, red),
and intestinal tract (IT, yellow).
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ID/cc, p < 0.0001) (Figure 6A). The whole body radioactivity
from C16-micelles at 24 (p < 0.0001) and 48 h (p < 0.0001) is
reduced significantly compared to C18-micelles (Figure 6B).
The β-phase blood circulation half-life (t1/2,β) of C16-micelles,
fit to a biphasic model, is 16.1 h, lower than that of C18-
micelles (29.5 h), as reported previously.18 These results
demonstrated higher in vivo stability of C18-micelles, with
extended blood circulation. The difference in blood circulation
time between the two micelles is larger than that shown by the
in vitro stability (Figure 3) and drug release kinetics (Figure 4).
The radioactivity observed for 64Cu-labeled C16-micelles, 48 h
after injection, is 3.1 ± 0.3% ID/g in the spleen, 4.3 ± 0.5% ID/
g in the liver, and 3.3 ± 0.1% ID/g in the kidney. The
accumulation of C18-micelles was similar in the liver and
kidney, but the spleen radioactivity of C16-micelles (p < 0.001)
was lower than that reported previously for C18-micelles
(Figure 6C).
The greatest differences in biodistribution between the C16-
and C18-micelle are in the tumor accumulation at 48 h after
injection. Transverse PET images (Figure 5) show that both
micelles accumulate in tumor, 24 h after administration. Figure
6D plots the accumulation of the two micelles in the tumor
tissue as a function of time. At 48 h, the accumulation levels for
C16- and C18-micelles are 3.7 ± 0.5% ID/g and 5.3 ± 0.6%
ID/g, respectively. The significantly higher activity from C18-
micelles (p < 0.0001) is consistent with their longer blood
circulation time that led to greater tumor accumulation. These
results are consistent with earlier studies that have shown
increased tumor uptake for nanocarriers with enhanced blood
circulation leading to more efficient passive targeting of the
tumor tissue.30,31 This amplification of the difference in the in
vivo stability and extent of tumor accumulation between C16-
and C18-micelles underscores the importance of the alkyl chain
length and hydrophobicity in the micelle design on their
pharmacokinetics.
The unique design of the 3-helix micelle shell based on PEG
conjugates of coiled-coil 3-helix bundles provides high stability
as compared to other nanocarriers in a similar size range. In
previous studies, we have established the importance of the
tertiary structure of the amphiphile headgroup on directional
repulsion between PEG chains that leads to high stability of 3-
helix micelles. The focus of this study is to delineate and
quantify the contribution from the core forming alkyl tails to 3-
helix micelle stability. Amphiphiles with C16 and C18 alkyl tails
form well-defined core−shell micelles, with uniform size
distribution as confirmed by DLS and SAXS measurements.
The alkyl tails in core of 3-helix micelles exhibit an endothermic
phase transition, with transition temperatures of 15 and 24 °C
for C16- and C18-micelles, respectively. C18-micelles exhibit
higher stability with a slower rate of subunit exchange, relative
to C16-micelles, in the presence of serum proteins at 37 °C.
The slower rate of DOX release from C18 micelles is in
agreement with their higher stability. Evaluation of pharmaco-
kinetics of radiolabeled C16- and C18-micelles by PET imaging
Figure 6. Quantitative analysis of PET images and biodistribution. (A) Blood radioactivity (%ID/cc) of 64Cu-labeled C16- and C18-micelles. Curves
were fit as two-phase exponential decay. For C16-micelles, the fit is given by Y = 36.61e−0.043t + 24.73e−0.74t, with t1/2,β = 16.12 h; and for C18-
micelles, the fit is given by Y = 45.32e−0.0235t + 16.42e−1.27t, with t1/2,β = 29.52 h. (B) Whole body radioactivity (normalized by initial value as 100%)
of 64Cu-labeled C16- and C18-micelles. (C) Biodistribution (%ID/g) of C16- and C18-micelles in major clearance organs. (D) Tumor accumulation
of micelles as a function of time shows that C18-micelles have significantly higher extent of tumor localization, 48 h after intravenous administration
(p < 0.0001). Statistical significance was determined by t tests (unpaired) corrected for multiple comparisons using the Holm-Sidak method, with α
= 5%.
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shows significantly longer blood circulation of C18-micelles
with half-life of 29.5 h, compared to 16.1 h for C16-micelles.
The differences between the two micelles in terms of their in
vivo circulation stability are more pronounced compared to the
differences in terms of in vitro stability and cargo release
kinetics. We speculate that the complex biological environment
in circulation including dynamic blood flow conditions and the
presence of a large number of proteins that act as traps for
amphiphilic assemblies have a critical impact on the distinction
between pharmacokinetics of injected carriers. These studies
underscore the significance of the thermal characteristics of
core forming alkyl chains on stability of 3-helix micelles in
conditions relevant to intravenous administration. Higher
transition temperature for melting of C18 chains, combined
with their higher hydrophobicity and lower mobility at
physiological temperature result in higher in vivo stability of
C18-micelles with longer blood circulation time and greater
extent of tumor accumulation. These results indicate that 3-
helix micelles based on C18 alkyl tails would be highly
promising for intravenous drug delivery intended for cancer
therapeutics. This systematic study allows comprehension of
the contribution of tail length on 3-helix micelle stability,
separately from the micelle headgroup. The results of this study
serve as important guidelines to determine the suitability of
nanocarriers based on 3-helix micelles with tunable in vivo
circulation times intended for different biological applications.
■ CONCLUSION
In summary, we present a systematic investigation of the effect
of alkyl chain length on size, core packing, in vitro stability,
cargo release kinetics, and pharmacokinetics of 3-helix micelles.
The present studies clearly show that the core forming alkyl
chains are an equally important design parameter that could be
used to tailor the stability and in vivo behavior of 3-helix
micelles. Enthalpy of the alkyl chain phase transition in C18-
micelles is higher compared to that in C16-micelles, consistent
with higher hydrophobic interactions between C18 chains.
C18-micelles exhibit higher stability with a slower rate of
subunit exchange, relative to C16-micelles, in the presence of
serum proteins at 37 °C. C18-micelles show slower and
extended cargo release compared to C16-micelles. The
diffusion constant for DOX release from C18-micelles is
approximately half of that from C16-micelles, in agreement
with their higher stability. The difference between the two
micelles in terms of their in vivo circulation stability and extent
of tumor accumulation are more pronounced compared to the
differences in the in vitro stability and cargo release kinetics.
The results from this study underscore the significance of




Structural characterization of 3-helix micelles with C16 and
C18 alkyl chains is provided. This material is available free of
charge via the Internet at http://pubs.acs.org.
■ AUTHOR INFORMATION
Corresponding Author
*E-mail: tingxu@berkeley.edu. Phone: 510-642-1632. Fax: 510-
643-5792.
Author Contributions
Nikhil Dube and Jai W. Seo contributed equally.
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
N.D. and T.X. were supported by National Institutes of Health
under contracts 1R21EB016947-01A1. H.D. was supported by
Office of Army of the U.S. Department of Defense under
contract W91NF-09-1-0374. J.Y.S. and R.L. were supported by
the Office of Basic Energy Sciences, of the U.S. Department of
Energy under contract DE-AC02-05CH11231. J.W.S., L.M.M,
and K.W.F. were supported by National Institutes of Health
under contracts NIHR01CA134659, NIHCA112356, and
NIHCA103828.
■ REFERENCES
(1) Kazunori, K.; Glenn S, K.; Masayuki, Y.; Teruo, O.; Yasuhisa, S. J.
Controlled Release 1993, 24, 119−132.
(2) Kwon, G. S.; Kataoka, K. Adv. Drug Delivery Rev. 1995, 16, 295−
309.
(3) Allen, C.; Maysinger, D.; Eisenberg, A. Colloids Surf., B 1999, 16,
3−27.
(4) Kataoka, K.; Matsumoto, T.; Yokoyama, M.; Okano, T.; Sakurai,
Y.; Fukushima, S.; Okamoto, K.; Kwon, G. S. J. Controlled Release
2000, 64, 143−153.
(5) O’Reilly, R. K.; Hawker, C. J.; Wooley, K. L. Chem. Soc. Rev.
2006, 35, 1068−1083.
(6) Matsumura, Y. Adv. Drug Delivery Rev. 2008, 60, 899−914.
(7) Matsumura, Y.; Kataoka, K. Cancer Sci. 2009, 100, 572−579.
(8) Peters, D.; Kastantin, M.; Kotamraju, V. R.; Karmali, P. P.;
Gujraty, K.; Tirrell, M.; Ruoslahti, E. Proc. Natl. Acad. Sci. U.S.A. 2009,
106, 9815−9819.
(9) Ebrahim Attia, A. B.; Ong, Z. Y.; Hedrick, J. L.; Lee, P. P.; Ee, P.
L. R.; Hammond, P. T.; Yang, Y.-Y. Curr. Opin. Colloid Interface Sci.
2011, 16, 182−194.
(10) Lu, J.; Owen, S. C.; Shoichet, M. S. Macromolecules 2011, 44,
6002−6008.
(11) Elsabahy, M.; Wooley, K. L. Chem. Soc. Rev. 2012, 41, 2545−
2561.
(12) Owen, S. C.; Chan, D. P. Y.; Shoichet, M. S. Nano Today 2012,
7, 53−65.
(13) Rösler, A.; Vandermeulen, G. W. M.; Klok, H.-A. Adv. Drug
Delivery Rev. 2012, 64, 270−279.
(14) Dube, N.; Shu, J. Y.; Dong, H.; Seo, J. W.; Ingham, E.;
Kheirolomoom, A.; Chen, P.-Y.; Forsayeth, J.; Bankiewicz, K.; Ferrara,
K. W.; Xu, T. Biomacromolecules 2013, 14, 3697−3705.
(15) Chen, H.; Kim, S.; He, W.; Wang, H.; Low, P. S.; Park, K.;
Cheng, J.-X. Langmuir 2008, 24, 5213−5217.
(16) Chen, H.; Kim, S.; Li, L.; Wang, S.; Park, K.; Cheng, J.-X. Proc.
Natl. Acad. Sci. U.S.A. 2008, 105, 6596−6601.
(17) Letchford, K.; Burt, H. M. Mol. Pharm. 2011, 9, 248−260.
(18) Dong, H.; Dube, N.; Shu, J. Y.; Seo, J. W.; Mahakian, L. M.;
Ferrara, K. W.; Xu, T. ACS Nano 2012, 6, 5320−5329.
(19) Allen, C.; Yu, Y.; Maysinger, D.; Eisenberg, A. Bioconjugate
Chem. 1998, 9, 564−572.
(20) Jette, K.; Law, D.; Schmitt, E.; Kwon, G. Pharm. Res. 2004, 21,
1184−1191.
(21) Adams, M. L.; Kwon, G. S. J. Biomater. Sci. 2002, 13, 991−1006.
(22) Yamamoto, Y.; Yasugi, K.; Harada, A.; Nagasaki, Y.; Kataoka, K.
J. Controlled Release 2002, 82, 359−371.
(23) Sun, X.; Rossin, R.; Turner, J. L.; Becker, M. L.; Joralemon, M.
J.; Welch, M. J.; Wooley, K. L. Biomacromolecules 2005, 6, 2541−2554.
(24) Diezi, T. A.; Bae, Y.; Kwon, G. S. Mol. Pharmaceutics 2010, 7,
1355−1360.
(25) Zhao, X.; Poon, Z.; Engler, A. C.; Bonner, D. K.; Hammond, P.
T. Biomacromolecules 2012, 13, 1315−1322.
Biomacromolecules Article
dx.doi.org/10.1021/bm5005788 | Biomacromolecules 2014, 15, 2963−29702969
(26) Perrault, S. D.; Walkey, C.; Jennings, T.; Fischer, H. C.; Chan,
W. C. W. Nano Lett. 2009, 9, 1909−1915.
(27) Popovic,́ Z.; Liu, W.; Chauhan, V. P.; Lee, J.; Wong, C.; Greytak,
A. B.; Insin, N.; Nocera, D. G.; Fukumura, D.; Jain, R. K.; Bawendi, M.
G. Angew. Chem., Int. Ed. 2010, 49, 8649−8652.
(28) Dong, H.; Shu, J. Y.; Dube, N.; Ma, Y.; Tirrell, M. V.; Downing,
K. H.; Xu, T. J. Am. Chem. Soc. 2012, 134, 11807−11814.
(29) Zinn, T.; Willner, L.; Lund, R.; Pipich, V.; Richter, D. Soft
Matter 2012, 8, 623−626.
(30) Gillies, E. R.; Dy, E.; Frećhet, J. M. J.; Szoka, F. C. Mol.
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Aranda, F. J. Int. J. Pharm. 2006, 325, 99−107.
(41) Gore, T.; Dori, Y.; Talmon, Y.; Tirrell, M.; Bianco-Peled, H.
Langmuir 2001, 17, 5352−5360.
(42) Kwon, G.; Naito, M.; Yokoyama, M.; Okano, T.; Sakurai, Y.;
Kataoka, K. J. Controlled Release 1997, 48, 195−201.
(43) Nystrom, A. M.; Xu, Z.; Xu, J.; Taylor, S.; Nittis, T.; Stewart, S.
A.; Leonard, J.; Wooley, K. L. Chem. Commun. 2008, 3579−3581.
(44) Lin, L. Y.; Lee, N. S.; Zhu, J.; Nyström, A. M.; Pochan, D. J.;
Dorshow, R. B.; Wooley, K. L. J. Controlled Release 2011, 152, 37−48.
(45) Teng, Y.; Morrison, M. E.; Munk, P.; Webber, S. E.; Prochaźka,
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